Prostate Cancer

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.

Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.

Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.

Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Recent FDA approval of the companion diagnostics may help improve personalized treatment decision-making for patients with prostate cancer.

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

“The machine learning algorithms based on pure clinical data aren’t any better, [but] that’s where prostate cancer algorithms are starting to shine,” said James B. Yu, MD, MHS, FASTRO.

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.

Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.

A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.

In addition to tissue biopsy, a liquid biopsy test can be used to better identify patients who may benefit from niraparib and abiraterone acetate.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.

Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.